Michael Andriole
Chief Executive Officer bei CHIMERIX, INC.
Vermögen: 473 842 $ am 31.03.2024
Profil
Michael T.
Andriole is currently the President, Chief Executive Officer & Director at Chimerix, Inc. Prior to his current position, he served as the Vice President-Corporate Business Development at Eli Lilly & Co. from 2014 to 2017.
He also worked as the Chief Financial Officer at Endocyte, Inc. in 2017 and 2018.
Mr. Andriole holds an MBA from Kelley School of Business and an undergraduate degree from Williams College of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CHIMERIX, INC.
0,50% | 14.02.2024 | 447 021 ( 0,50% ) | 473 842 $ | 31.03.2024 |
Aktive Positionen von Michael Andriole
| Unternehmen | Position | Beginn |
|---|---|---|
| CHIMERIX, INC. | Chief Executive Officer | 01.08.2023 |
Ehemalige bekannte Positionen von Michael Andriole
| Unternehmen | Position | Ende |
|---|---|---|
| ENDOCYTE, INC. | Director of Finance/CFO | 01.12.2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.02.2017 |
Ausbildung von Michael Andriole
| Kelley School of Business | Masters Business Admin |
| Williams College of Business | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CHIMERIX, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
